AstraZeneca PLC (AZN)

NASDAQ: AZN · Real-Time Price · USD
65.29
+0.10 (0.15%)
At close: Nov 13, 2024, 4:00 PM
65.33
+0.04 (0.06%)
Pre-market: Nov 14, 2024, 9:16 AM EST
0.15%
Market Cap 200.03B
Revenue (ttm) 51.21B
Net Income (ttm) 6.50B
Shares Out 1.55B
EPS (ttm) 4.15
PE Ratio 30.80
Forward PE 13.99
Dividend $1.48 (2.27%)
Ex-Dividend Date Aug 9, 2024
Volume 6,050,852
Open 65.49
Previous Close 65.19
Day's Range 64.69 - 65.70
52-Week Range 60.47 - 87.68
Beta 0.18
Analysts Buy
Price Target 88.80 (+36.01%)
Earnings Date Nov 12, 2024

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]

Sector Healthcare
IPO Date May 12, 1993
Employees 89,900
Stock Exchange NASDAQ
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $88.8, which is an increase of 36.01% from the latest price.

Price Target
$88.8
(36.01% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity

AstraZeneca PLC aims for $80 billion revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight management p...

15 hours ago - Seeking Alpha

Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to purchase Summa Health for $485 million.

1 day ago - CNBC

AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript

AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO Arad...

1 day ago - Seeking Alpha

AstraZeneca Lifts Outlook, Plans $3.5B US Investment

British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the ...

1 day ago - Investopedia

AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'

AstraZeneca Plc AZN reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.

1 day ago - Benzinga

AstraZeneca: 450 million pound investment in UK under review amid talks with govt

London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with th...

1 day ago - Reuters

AstraZeneca says detained China head has lawyer, but company still in dark

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on Tuesd...

2 days ago - Reuters

AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company's research and manufacturing footprint by the ...

2 days ago - Business Wire

AstraZeneca's 9M and Q3 2024 results

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary     9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance...

2 days ago - Business Wire

AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines, after ...

2 days ago - Reuters

Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have submitted a new Biologics License Application (BLA) for accelerated approval in the ...

2 days ago - Business Wire

Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans voted on abortion access.

Other symbols: VKTX
5 days ago - CNBC

ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.

6 days ago - Business Wire

TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZene...

6 days ago - Business Wire

AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy the stock as the big picture looks positive. The company's numbers were strong in H1 2024 and its earn...

6 days ago - Seeking Alpha

AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66th American Society o...

7 days ago - Business Wire

China Has Detained a Senior AstraZeneca Executive

Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese government is probing AstraZeneca employees, the drugmaker says.

7 days ago - WSJ

AstraZeneca: China's investigation into exec separate from medical insurance probe

AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top executive, Leon Wang, is separate from a large health insurance fraud case al...

8 days ago - Reuters

AstraZeneca Shares Slide As Execs in China Face Fraud Investigation

AstraZeneca (AZN) shares dropped Tuesday after a report that dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case, according to a report from ...

8 days ago - Investopedia

AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill.

8 days ago - Market Watch

AstraZeneca shares fall on report of potential China probe fallout

AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fr...

8 days ago - Reuters

AstraZeneca says experimental obesity pill safe and tolerable in early-stage trial

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.

9 days ago - Reuters

AstraZeneca Probe in China Adds to Concerns for Foreign Businesses

An investigation involving the drugmaker's China president is the latest industry crackdown to trigger uncertainty about Beijing's intentions.

13 days ago - WSJ

AstraZeneca says its China operations president under investigation

AstraZeneca said on Wednesday the company's China President Leon Wang is currently under investigation and is cooperating with Chinese authorities.

15 days ago - Reuters

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)-base...

15 days ago - Business Wire